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Purpose: To determine the safety and efficacy of hypofractionated intensity modulated radiation therapy (Hypo-IMRT)
using helical tomotherapy (HT) with concurrent low dose temozolomide (TMZ) followed by adjuvant TMZ in patients
with glioblastoma multiforme (GBM).
Methods and materials: Adult patients with GBM and KPS > 70 were prospectively enrolled between 2005 and 2007
in this phase I study. The Fibonacci dose escalation protocol was implemented to establish a safe radiation
fractionation regimen. The protocol defined radiation therapy (RT) dose level I as 54.4 Gy in 20 fractions over 4 weeks
and dose level II as 60 Gy in 22 fractions over 4.5 weeks. Concurrent TMZ followed by adjuvant TMZ was given
according to the Stupp regimen. The primary endpoints were feasibility and safety of Hypo-IMRT with concurrent TMZ.
Secondary endpoints included progression free survival (PFS), pattern of failure, overall survival (OS) and incidence of
pseudoprogression. The latter was defined as clinical or radiological suggestion of tumour progression within three
months of radiation completion followed by spontaneous recovery of the patient.
Results: A total of 25 patients were prospectively enrolled with a median follow-up of 12.4 months. The median age at
diagnosis was 53 years. Based on recursive partitioning analysis (RPA) criteria, 16%, 52% and 32% of the patients were
RPA class III, class IV and class V, respectively. All patients completed concurrent RT and TMZ, and 19 patients (76.0%)
received adjuvant TMZ. The median OS was 15.67 months (95% CI 11.56 - 20.04) and the median PFS was 6.7 months
(95% CI 4.0 – 14.0). The median time between surgery and start of RT was 44 days (range of 28 to 77 days). Delaying
radiation therapy by more than 6 weeks after surgery was an independent prognostic factor associated with a worse
OS (4.0 vs. 16.1 months, P = 0.027). All recurrences occurred within 2 cm of the original gross tumour volume (GTV). No
cases of pseudoprogression were identified in our cohort of patients. Three patients tolerated dose level I with no dose
limiting toxicity and hence the remainder of the patients were treated with dose level II according to the dose
escalation protocol. Grade 3–4 hematological toxicity was limited to two patients and one patient developed Grade 4
Pneumocystis jiroveci pneumonia.
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Conclusion: Hypo-IMRT using HT given with concurrent TMZ is feasible and safe. The median OS and PFS are
comparable to those observed with conventional fractionation. Hypofractionated radiation therapy offers the
advantage of a shorter treatment period which is imperative in this group of patients with limited life expectancy.
Keywords: GBM, Concurrent RT and TMZ, Hypofractionation, IMRT, Phase I studyIntroduction
GBM, a WHO grade IV glioma, is the most common and
most malignant primary central nervous system tumour.
Currently, the standard of care for these patients is safe,
maximal surgical resection, if possible, followed by posto-
perative RT with concomitant TMZ followed by six cycles
of adjuvant TMZ as established by the 22981/26981–
EORTC/NCIC phase III trial [1]. The median survival
with this multimodality treatment is approximately 14 -
months [1].
The standard radiation dose is 60 Gy in 1.8-2.0 Gy per
fraction given over 6 weeks. Most dose escalation studies
were done before the era of intensity modulated radiation
therapy (IMRT). Two main studies have examined the use
of IMRT in delivering hypofractionated postoperative ra-
diation therapy alone [2,3]. The use of IMRT is considered
to allow selective delivery of high dose per fraction to the
target volume while maintaining the dose to surrounding
normal tissues below certain threshold doses [2]. More-
over, hypofractionation confers the benefits of abbreviating
the RT course in patients with a limited life expectancy,
reducing costs, and possibly increasing malignant cell
killing and decreasing accelerated repopulation [2,3]. Re-
cently, Panet-Raymond et al. [4] retrospectively studied
the feasibility of delivering Hypo-IMRT with concurrent
and adjuvant TMZ on a cohort of 35 patients. The median
survival was found to be comparable to that after conven-
tional fractionation and the regimen was tolerable with no
undue toxicity. The use of helical tomotherapy (HT) can
provide different geometric flexibility and modulation
techniques over standard IMRT. Such superior control of
dose distribution could allow for better dose uniformity
within the target and/ or sparing of organs at risk [5].
The optimal hypofractionation regimen using IMRT is
yet to be determined. In the study by Floyd et al. [2], a
dose of 50 Gy at 5 Gy per fraction was given to the enhan-
cing primary tumour, residual disease or surgical cavity
with a simultaneous dose of 30 Gy at 3 Gy per fraction to
the surrounding oedema. A high rate of cerebral necrosis
was noted using this regimen which resulted in earlier
termination of patient enrolment. Sultamen et al. [3]
prescribed 60 Gy in 20 fractions to the GTV and 40 Gy in
20 fractions to the PTV in their study. In this study, one
patient developed blindness 9 months after the comple-
tion of radiation treatment but according to the author, it
was not felt to be secondary to RT as the dose to the opticchiasm in this patient was 40 Gy with a dose per fraction
of 2 Gy.
Our study is one of the few studies that examine the effi-
cacy and safety of delivering Hypo-IMRT using HT with
concomitant and adjuvant TMZ in patients with GBM. In
this phase I study, a dose escalation protocol using two
dose levels, was also used to determine a safe radiation
fractionation regimen. Given the toxicity reported in the
above mentioned studies, we elected to maintain the dose
per fraction below 3 Gy for both dose levels, [2,3]. The
delivery of Hypo-IMRT with concomitant and adjuvant
TMZ was found to be safe and feasible. The PFS and OS




Adult patients with a histologically confirmed diagnosis
of GBM were enrolled between 2005 and 2007. Eligibil-
ity criteria included age ≥ 18, KPS ≥ 70, no prior RT to
the head or neck area, no prior use of chemotherapy or
radio-sensitizer drugs, and normal hematologic, hepatic
and renal function. Ethics approval was obtained from
Alberta Cancer Ethics Review Board and all patients
signed a study-specific consent form. All patients were
initially evaluated with a complete history and a detailed
neurological evaluation and underwent a computerized
tomography (CT) scan and/ or magnetic resonance im-
aging (MRI) preoperatively. Extent of surgical resection
was recorded based on operative report and postoperative
imaging.
Radiation therapy
All patients were treated with HT using a 6 MV linear
accelerator. Patients were immobilized with a thermo-
plastic mask of the head, neck and upper shoulders for
simulation and treatment. Patients underwent CT simu-
lation where all irradiated tissues were imaged using
0.3 cm thick slices. An MRI in the treatment position
with the same immobilization device was also obtained
and fused with the CT images. The GTV was defined as
areas of contrast enhancement on T1-weighted images
on registered MRI images. The clinical target volume
(CTV) included the GTV with a non-uniform 1 cm
margin, excluding areas extending beyond the dura,
calvarium or other anatomical boundaries. The planning
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margin. A dose escalation protocol was implemented. This
mandated treating at least 3 patients using dose level I
which was defined as 54.4 Gy in 20 fractions over 4 weeks.
The biologically effective dose (BED) of which was
calculated to be 62.2 Gy at 2 Gy per fraction based on the
linear-quadratic model with the α/β ratio assumed to be
10 Gy for the tumour. The absence of any dose limi-
ting toxicity, defined as an acute Grade 4 neurological
radiation-induced toxicity within 30 days of starting radi-
ation, in all of the 3 patients allowed moving into dose
level II which was defined as 60 Gy in 22 fractions over
4.5 weeks. The BED of dose level II was calculated to be
68.6 at 2 Gy per fraction based on the same principle. The
presence of a single case with a dose limiting toxicity
required treating an additional three patients with dose
level I and an additional dose limiting toxicity mandated
dose reduction for all further patients to 51.4 Gy in19
fractions. The dose was prescribed to at least 95% of the
PTV and was delivered in a single phase. Organs at risk
(OAR) including the optic nerves, optic chiasm, optic ap-
paratus (right and left optic nerves and optic chiasm),
brainstem, spinal cord and right and left eyes were
contoured in each slice. Treatment plans were generated
using the Hi-Art II System (TomoTherapy Inc., Madison,
WI). The jaw width, pitch, and modulation factor used for
our study were 2.5, 0.430, and 3 cm, respectively. The dose
calculation grid resolution was 2 mm. The average num-
ber of iterations for a particular plan was approximately
20. The planning objective was to deliver the specified
dose to at least 95% of the PTV while minimizing the dose
to the defined OAR. For critical structures, the maximum
importance was given to the optic chiasm followed by the
brainstem, optic nerves, and spinal cord (if the cord was
considered to be in the vicinity of the tumor). The dose
constraints for the aforementioned organs were a max-
imum dose of 50 Gy for brainstem, 40 Gy for spinal cord,
45 Gy for the optic chiasm and optic nerves, and 10 Gy
for the orbits. Dose-volume histograms were generated for
all critical structures to ensure that the dose delivered was
within accepted tolerance levels. A megavoltage CT scan
was obtained prior to each fraction for verification of
treatment position. A more than 5 mm displacement of
the isocenter mandated repositioning of the patient. At
our institution, for dose quality assurance (DQA), a cheese
phantom is used to measure film and ionisation chamber
dosimetry for each RT plan prior to commencing treat-
ment. Criteria for a satisfactory treatment delivery include
a point dose measurement, taken in a high dose and low
gradient region within 2% of the calculated dose and
gamma index with a distance to agreement goal of 3 mm
and a percent dose difference goal of 5%. These criteria
have been verified at our institution and the details of the
DQA process have been previously published [6].Chemotherapy
Patients were given TMZ at dose of 75 mg/m2/ day con-
comitant with RT, beginning the day of the first fraction
of radiation, including weekends and holidays and
ending on the day of the last radiation fraction. This was
followed by up to 6 cycles of adjuvant TMZ at a dose of
150–200 mg/ m2 daily for 5 days every 28 days, as
per the EORTC/NCIC protocol [1]. All of the patients
received Trimethoprim-Sulfamethoxazole for prophy-
laxis against Pneumocystis jiroveci pneumonia.Patient assessment and outcome
In this phase I study, patients were assessed weekly during
RT with clinical examination, Karnofsky performance sta-
tus, complete blood counts, renal function tests and liver
enzymes. After completion of RT, patients were followed-
up every three months with clinical evaluation and an
MRI. Blood chemistry was obtained at the 3- and 6-
months visits and as needed thereafter. The common ter-
minology criteria for adverse events (CTC-AE) were used
for grading acute and late side effects. When disease pro-
gression was suspected on clinical basis, an MRI was done
for confirmation. Response to treatment was classified
according to the RECIST criteria. The primary endpoints
were feasibility and safety of Hypo-IMRT with concurrent
TMZ. The feasibility of the study was assessed by deter-
mining the ability to enroll our predetermjined sample
size, practicality of planning and delivering Hypo-IMRT
using HT, and the ability to achieve the specified planning
goals with the use of HT. Secondary endpoints included
PFS, pattern of failure, OS and incidence of
pseudoprogression. PFS was defined from the day of sur-
gery till the documentation of disease progression clinic-
ally and/ or radiologically. OS was measured from
registration till death. Pseudoprogression was defined as
clinical or radiological suggestion of tumor progression
within three months of radiation completion followed by
spontaneous recovery of the patient [7].Statistical analysis
Descriptive analysis was conducted for all study variables.
Mean, standard deviation, median (range) were reported
for continuous variables, frequency and percentages were
reported for the categorical variables. PFS and OS were
analyzed using the Kaplan-Meier method. A univariate
analysis using the Cox proportional regression analysis
was used to examine the effect of multiple prognostic
factors on PFS and OS. These factors included KPS, recur-
sive partitioning analysis (RPA) class [8], type of surgery
performed (biopsy vs. subtotal or gross total resection),
time interval between the surgery and start of RT
and number of adjuvant Temozolomide cycles. Factors
Table 2 Protocol treatment goals
Volume Goal 1 G
PTV 60 Gy to ≥ 95% of the PTV ≤
Optic Chiasm ≤ 5% to > 47.25 Gy ≤
Optic nerves ≤ 5% to > 47.25 Gy ≤
Brainstem ≤ 5% to > 52.5 Gy ≤
Spinal cord ≤ 5% to > 42 Gy ≤
Eyes ≤ 5% to > 10.5 Gy ≤
Abbreviations: PTV: planning target volume.



















Central (pineal, cerebellum) 2 8
Type of surgery
Gross total resection 3 12
Subtotal resection 12 52







Patients who completed >2 cycles 12 48
Abbreviations: RPA: recursive partitioning analysis; KPS: Karnofsky perfomans
status; TMZ: Temozolamide.
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were then analyzed using the multivariate Cox model. All
reported p values are two-sided and differences were
considered statistically significant when the p value was
<0.05. The SAS program (Version 9.1, SAS Institute Inc.,
Cary, NC, USA) was used for the statistical analysis.
Results
Patient characteristics
Between April 2005 and July 2007, 25 patients with
histologically proven GBM were prospectively treated with
Hypo-IMRT using HT, with concurrent low dose TMZ
chemotherapy followed by adjuvant TMZ according to
the above-described protocol. The median follow-up of
patients included in the analysis was 12.4 months (range,
1.7 to 38.5 months). The patients’ baseline characteristics
are summarized in Table 1. The median age at diagnosis
was 53.1 years (range, 22.6 - 73.4 years). Patients were
classified according to the RTOG RPA criteria. Almost
half of the patients (52%) were RPA class IV and the
remaining was either class III (16%) or V (32%). Twelve,
three and nine patients underwent subtotal resection,
gross total resection and biopsy only, respectively.Treatment goals and treatment delivery
All of the patients completed RT with concurrent TMZ
with no treatment delay or interruption. The median
time for starting RT from the date of surgery was 43 days
(range, 28–77 days). Three patients were treated with
dose level I (54.4 Gy in 20 fractions over 4 weeks) and
none of them developed any of the defined dose-limiting
toxicity. This allowed proceeding to dose level II to
which the remainder of the patients was treated as per
the aforementioned dose escalation protocol. The treat-
ment goals are as described in Table 2.
The dose–volume analysis for the PTV and OARs is
showed in Table 3. The PTV volume ranged from 102.8
to 427.7 cm3 (mean 264.3 ± 84.7 cm3). The mean dose
to the PTV was 60.8 Gy (SD ± 2.7; range 43.6 - 65.6).
The maximum dose received by the optic chiasm, optic
nerves and brain stem was 40.5 Gy ± 7.6, 34.6 Gy ±
11.5, and 50.7 Gy ± 10.3, respectively. The dose to theoal 2 Goal 3
20% of the PTV to > 66 Gy ≤ 1% of the PTV to < 54 Gy
33% to 40.5 Gy
33% to 40.5 Gy
33% to 45 Gy
33% to 36 Gy
33% to 9 Gy
Table 3 Dose–volume analysis for planning target volume
and organs at risk
Volume Parameter Mean ± SD
PTV Mean dose 60.8 ± 2.7 Gy
Minimum dose 43.6 ± 9.4 Gy




1.1 ± 0 (Range 1.0 - 1.2)
Optic chiasm Mean dose 30.4 ± 7.2 Gy
Maximum dose 40.5 ± 7.6 Gy
V40 13.9 ± 15.9%
V45 0.8% ± 1.9%
V47.25 0%
V50 0%
Left optic nerve Mean dose 18.3 ± 8.0 Gy
Maximum dose 29.5 ± 11.1 Gy
V40 3.6 ± 9.1%
V47.25 0.1 ± 0.3%
V50 0
Right optic nerve Mean dose 23.4 ± 10.3 Gy
Maximum dose 34.6 ± 11.5 Gy
V40 13.6 ± 21.8%
V47.25 0%
V50 0%
Brainstem Mean dose 22.8 ± 10.2 Gy
Maximum dose 50.7 ± 10.3 Gy
V40 19.8 ± 19%
V50 4.5 ± 7.4%
V52.5 1.3 ± 3%
V55 0.4 ± 1%
Spinal cord Mean dose 1.2 ± 0.8 Gy
Maximum dose 3.1 ± 2.4 Gy
V40 0%
V42 0%
Left eye Mean dose 5.2 ± 2.8 Gy
Maximum dose 11.1 ± 4.1 Gy
V10.5 5 ± 17.7%
Right eye Mean dose 5.7 ± 3.7 Gy
Maximum dose 13.3 ± 6.4 Gy
V10.5 5.6 ± 17%
Table 4 Acute toxicity associated with concurrent RT/
TMZ
Grade
Toxicity 1 2 3 4
Gastrointestinal 1 6 0 0
Hematological
Thrombocytopenia 0 0 1 1
Neutropenia 0 2 1 0
Anemia 1 0 1 0
Infection 0 2 0 1
Abbreviations: RT: radiation therapy; TMZ: temozolamide.
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maximum was 3.1 Gy ± 2.4. Seventy six percent of the
treated cohort received adjuvant TMZ but only 48% of
the patients completed 3 or more cycles. Of the patients
who failed to complete 6 cycles of adjuvant TMZ, 14
of them were due to disease progression. Two patientsdeclined further therapy and treatment was discontinued
due to treatment related side effects in three patients,
two of them had persistent thrombocytopenia.Treatment toxicity
Concurrent RT and TMZ related acute side effects are
reported in Table 4. One patient developed Pneumocys-
tis jiroveci pneumonia infection requiring admission to
the intensive care unit (ICU) for ventilatory support.
Grade 3 and/or 4 myelosuppressive toxicity developed
in two patients precluding the ability to give adjuvant
TMZ. The remainder of the patients tolerated the treat-
ment with mild or no acute toxicity.Prognostic factors and outcome
At a median follow-up of 12.4 months, the median OS
was 15.67 months (95% CI 11.56 - 20.04) and the me-
dian PFS was 6.7 months (95% CI 4.0 – 14.0) (Figure 1).
PFS at 6 months was 60% (95% CI 40 – 78) and PFS at
12 months was 38% (95% CI 20 – 58). All the cases of
disease recurrence were either local or marginal i.e.
within 2 cm of the tumour bed. Nine patients progressed
within three months of the completion of RT. We did
closely investigate these cases to avoid overlooking cases
of pseudoprogression. However, none was identified in
our cohort of patients. We investigated the potential asso-
ciation between several prognostic factors and increa-
sed risk of GBM progression. A univariate analysis was
performed on the following factors: KPS (≥80 vs. < 80),
RPA class (class III vs. class IV and V), type of surgery
performed (biopsy vs. subtotal or gross total resection),
time interval between the surgery and start of RT (≥ 6 weeks
vs. < 6 weeks), and number of adjuvant Temozolomide
cycles (administration of <3 vs. ≥3 cycles). On multivariate
analysis, the administration of 3 or more cycles of adjuvant
TMZ (versus <3 cycles) was associated with better OS (HR
0.83 [95% CI 0.69-0.99]; P-value 0.042) and better PFS (HR
0.79 [95% CI 0.65-0.96]; P-value 0.020). In addition, ≥ 6 -
weeks elapsed time between surgery and the start of ra-
diation therapy (versus < 6 weeks) was predictive of worse
Figure 1 Kaplan-Meier curve for overall survival and
progression free survival.
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more, higher KPS ≥ 80 (versus < 80) was associated with
improved PFS (HR 0.29 [95% CI 0.09-1.00]; P-value 0.049).
These results are summarized in Tables 5 and 6.
Discussion
Hypo-IMRT using HT is an approach that combines high-
precision RT delivery and a hypofractionated regimen.
Patients with GBM have a dismal prognosis and a limited
life span. The period of best performance is even shorter
as clinical deterioration is associated with profound mor-
bidity. Thus, achieving similar clinical outcome while
abbreviating treatment course can be of great clinical sig-
nificance. An additional advantage to hypofractionation is
the potential of improving tumour control. Our study is
the first to prospectively examine the use of Hypo-IMRTTable 5 Univariate and multivariate analysis of prognostic fac
Variable HR
KPS
≥ 80 vs. 70 0.4
RPA class
Class III vs. Class IV and V 0.34
Adjuvant TMZ
≥3 cycles vs. < 3 cycles 0.84
Extent of resection
GTR vs. biopsy or STR 0.54
Time interval between the date of surgery and start of RT
≥ 6 weeks vs. < 6 weeks 1.08
Abbreviations: PFS: progression free survival; HR: hazard ration; CI: confidence interv
Temozolomide; GTR: gross total resection; STR: subtotal resection; RT: radiation therwhile administering concurrent and adjuvant TMZ for
newly diagnosed GBM patients. The efficacy and safety of
this regimen were demonstrated by this phase I study.
Our data are consistent with the results reported by Stupp
et al. [1] with a median OS of 15.67 months a median PFS
of 6.7 months. The study’s inability to show improved out-
come, over standard fractionation, could be due to our re-
luctance to proceed to higher dose levels or merely a
reflection of the small sample size tested.
The risk of neurological side effects, particularly
radionecrosis of the brain is considered to be the main de-
terrent of using a hypofractionated scheme. The threshold
fraction size above which this risk is clinically significant is
difficult to determine. One reason is the considerable vari-
ation in the fractionation regimens used [9] and the major
difference in the prognostic characteristics of the patients
in whom the regimen was studied. In addition, most of
the dose escalation literature is based on conventional
methods of radiation delivery. The use of IMRT, HT
in particular, is thought to physically allow dose escalation
while keeping reasonable dose constraints to at risk
normal tissue. Two main studies have prospectively
investigated the use of IMRT to deliver a hypofractionated
radiation therapy to patients with GBM and each used a
different regimen [2,3]. Floyd et al. [2], used a dose of
50 Gy at 5 Gy per fraction given to the enhancing primary
tumour, residual disease or surgical cavity with a simultan-
eous dose of 30 Gy at 3 Gy per fraction to the surrounding
oedema. Twenty percent of the patients evaluated for late
toxicity experienced Grade 4 cerebral necrosis. The latter
study by Sultamen et al. [3] prescribed 60 Gy in 20
fractions to the GTV and 40 Gy in 20 fractions to the
PTV in their study. One patient developed blindness
9 months after the completion of radiation treatment but
the aetiology of the visual loss was not felt to be attribut-
able to RT. There is a wide range between the fractionstors for PFS
Univariate Multivariate
95% CI P HR 95% CI P
0.16-0.99 0.048 0.29 0.09-1.00 0.049
0.10-1.11 0.075 NS
0.72-0.982 0.028 0.79 0.65-0.96 0.02
0.15-1.91 0.339 NS
0.45-2.59 0.867 NS
al; KPS: Karnofsky performance status; RPA: recursive partitioning analysis; TMZ:
apy.
Table 6 Univariate and multivariate analysis of prognostic factors for OS
Univariate Multivariate
Variable HR 95% CI P HR 95% CI P
KPS
≥ 80 vs. 70 1.32 0.50-3.46 0.573 NS
RPA class
Class III vs. Class IV and V 2.51 0.56-11.20 0.228 NS
Adjuvant TMZ
≥3 cycles vs. < 3 cycles 0.79 0.64-0.97 0.024 0.83 0.69-0.99 0.042
Extent of resection
GTR vs. biopsy or STR 1.99 0.45-8.86 0.368 NS
Time interval between the date of surgery and start of RT
≥ 6 weeks vs. < 6 weeks 3.18 1.20-8.40 0.02 2.94 1.06-8.18 0.039
Abbreviations: OS: overall survival; HR: hazard ration; CI: confidence interval; KPS: Karnofsky performance status; RPA: recursive partitioning analysis; TMZ:
Temozolomide; GTR: gross total resection; STR: subtotal resection; RT: radiation therapy.
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of concurrent and adjuvant TMZ as the standard of care
for GBM, diminishes somewhat the applicability of these
previous studies to current treatment considerations. The
concern of an increased risk of cerebral radionecrosis with
the addition of chemotherapy is a valid one based on pre-
vious reports [7]. Panet-Raymond et al. [4] did a retro-
spective analysis on 35 patients who were treated with
post-operative Hypo-IMRT and TMZ according to the
Stupp protocol. In this study a total dose of 60 Gy in 20
daily 3-Gy fractions was delivered to the GTV while en-
suring that the 95–100% isodose line covered the GTV,
and the 65–70% line encompassed the PTV. The median
overall survival was 14.4 months, and the median disease-
free survival was 7.7 months, both of which were compar-
able to those reported by the EORTC/NCIC trial [1]. No
late toxicity was seen in that cohort of patients but
considering their method of prescribing the dose, the PTV
could have received a dose per fraction as low as 2 Gy
which is not different from conventional fractionation. In
our study, we used a dose escalation protocol to establish
a safe and tolerable fractionation regimen and no late tox-
icity was reported with either dose levels. Of interest, a re-
cently published phase I trial of Hypo-IMRT with TMZ
used a dose escalation protocol [10]. The study included
16 patients and examined four dose levels. A total dose of
60 Gy in 3 Gy/fraction, 4 Gy/fraction, 5 Gy/fraction, and
6 Gy/fraction, was prescribed in dose levels 1, 2, 3 and 4,
respectively. One patient who was treated at level 2 with
60 Gy in 4 Gy/fraction developed Grade 4 visual loss at
7 months following RT. Three patients developed patho-
logically confirmed extensive necrosis. One was treated at
level 1, one at level 2 and the third at level 4. Therefore,
most of the up-to-date hypofractionation studies suggest
that fraction sizes larger than 3 Gy could be highly
associated with detrimental late effects.With regard to acute toxicity, two patients in our study
developed Grade 3–4 myelosuppression which is expected
given the toxicity profile reported in the EORTC/NCIC
trial [1]. One patient developed severe Pneumocystis
jiroveci pneumonia infection requiring ICU admission.
This has been previously reported in patients with brain
tumours [11] and because of which prophylaxis against
this opportunistic infection was mandatory for all patients
receiving TMZ in the EORTC/NCIC trial. All of our
patients completed concurrent chemoradiation but only
76% of the patients received adjuvant TMZ. The median
number of adjuvant TMZ cycles was 2 and in the
EORTC/NCIC trial, the median number was 3. However,
due to the small sample size of our study, it is difficult to
conclude whether the intensified radiation dose could
have reduced the patients’ tolerance to adjuvant TMZ.
Two patients had persistent thrombocytopenia precluding
the use of adjuvant TMZ. The impact of thrombocytopenia
was examined in a retrospective analysis of 52 consecutive
patients with newly diagnosed high-grade gliomas treated
with the Stupp protocol [12]. The rate of Grade 3–4
thrombocytopenia was found to be 19% with a significant
risk of prolonged, possibly irreversible, low platelet count.
On multivariate analysis, we found that the administration
of 3 or more cycles of adjuvant TMZ was associated with
better OS and PFS. Our current guidelines suggest 6 cycles
of adjuvant TMZ as per EORTC/NCIC trial [1]. However,
the optimal duration of this adjuvant therapy, beyond six
months, is currently being prospectively investigated.
Despite the use of conformal RT, disease recurrence
occurs in the treatment volume in the majority of
patients [13]. The rate of recurrence outside the tumour
bed is low and mostly occurs with or after recurrence of
the original disease [14]. Brandes et al. [15] has recently
reported the pattern of failure in 95 patients with newly
diagnosed GBM treated with radiotherapy plus
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failure from local or marginal locations to distant
locations was observed. Recurrences outside the treatment
field were observed in 20% of the patients. Furthermore,
there was a significant higher survival rate in patients with
recurrence outside the RT fields (median survival of 26.1 -
months vs. 17.3 months). This change in the recurrence
pattern was not mirrored in our study which could be due
to the small sample size of our cohort. The same study by
Brandes et al. [15] also reported strong correlation between
the recurrence pattern and the MGMT methylation status.
The rate of infield recurrence correlated significantly with
MGMT methylation status. The rate was higher in patients
with unmethylated MGMT versus those with methylated
MGMT (85% vs. 57.9%). This factor could not be assessed
in our study as MGMT methylation was unfortunately not
tested in our patients.
The incidence of pseudoprogression has been variably
reported in the literature. Brandes et al. [16] reported
the incidence of pseudoprogression among 103 patients
treated with TMZ concurrent with and adjuvant to RT.
Out of 50 patients who developed radiological progression
as assessed by MRI done 4 weeks after treatment comple-
tion, 32 (64%) were identified to have pseudoprogression.
On the other hand, the data published by Sanghera et al.
[17] on a series of 104 patients, only 7 patients (32%) were
found to have pseudoprogression out of 22 classified to
have early disease progression as indicated by an MRI
8 weeks post-RT. During the 3 month period after the
concurrent treatment, radiation-induced brain injury
could be associated with an increase of non-enhancing
and enhancing tumour component on MRI. In our study,
unless otherwise clinically indicated, an MRI was first rou-
tinely performed after three months of the end of RT.
Accordingly, only nine cases were classified as early pro-
gression and all of which were true disease progression.
This could reflect the fact that neuroradiological imaging
was avoided during the early period following RT during
which radiation induced CNS injury, manifested as an in-
crease in contrast enhancement and/or non-enhancing
tumour components, is at its peak.
The RPA class is one of the most significant prognostic
factors that determine survival in patients with GBM. This
has also been shown to hold true in the era of concurrent
RT and TMZ (18). Unexpectedly, the RPA in our cohort
of patients did not correlate with survival. The most likely
explanation is that only patients with a KPS ≥70 were
included in our study. This resulted in clustering of the
majority of patients within one RPA class and due to our
small sample size; the effect of the RPA class could not be
statistically appreciated. Blumenthal et al. reported a large
analysis on the effect of the time to initiate RT following
surgery for GBM patients (19). Approximately, three thou-
sand patients, from the Radiation Therapy OncologyGroup (RTOG) database, were examined. The median
survival was found to be significantly greater in patients in
whom RT was started more than 4 weeks from surgery.
All of the patients started RT within 6 weeks as mandated
by all the study protocols according to these patients were
treated. The authors of the study concluded that short
delays in initiating RT, not exceeding 6 weeks, may not
significantly affect survival but cautioned that the reported
observation could reflect physician’s tendency to expedite
treatment in patients with worse outlooks resulting in ap-
parently worse outcome when RT was started earlier. In
our study, delays greater than 6 weeks in initiating RT ad-
versely affected outcome. The influence of delaying RT
could have been potentiated by the presence of consider-
able proportion (36%) of patients who only had a biopsy
for a tumour notorious for its short doubling time.
In summary, the results of this phase I dose-escalation
study have shown that Hypo-IMRT, using HT, with concur-
rent TMZ is safe and feasible. Our data are consistent with
results reported EORTC/NCIC trial, with a median OS of
15.67 months a median PFS of 6.7 months. The Hypo-
IMRT regimen is shorter than standard RT schedules. Ab-
breviating the RT regimen can be clinically meaningful
considering the life expectancy of patients with GBM. It is
hoped that these advanced technologies can provide better
quality of life, more convenient treatment options, and op-
timal utilization of the resources by health care providers.
Our findings warrant further validation of the results by
conducting a phase II randomized controlled trial compar-
ing our treatment regimen to conventional fractionation.
Careful progression through higher dose levels, in the set-
ting of a clinical trial seems possible.
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